clostridium difficile-associated disease (cdad) module
TRANSCRIPT
Multidrug-Resistant Organism (MDRO)and
Clostridium difficile-Associated Disease (CDAD) Module
Katherine Allen-Bridson, RN, BSN, CICDivision of Healthcare Quality PromotionCenters for Disease Control and Prevention
Background
First Tier: General Recommendations For All Acute Care Settings
Second Tier: Intensified Interventionse.g., chlorhexidine washes, active surveillance testing for MRSA
If endemic rates not decreasing, orif first case of important organism
What Metrics?
HICPAC Guidance On Management of MDROs in
Healthcare Settings (8/10/2006)
SHEA/HICPAC Position Paper (October 2008): Recommendations for MDRO Metrics
in Healthcare Settings
Define reasonable and practical metrics to best measure impact of prevention
Authors from APIC, CDC, SHEA, HICPAC
Five Categories of MDRO Outcome Measures1.
Tracking Patients2.
Monitoring Susceptibility Patterns3.
Estimating Infection Burden4.
Estimating Exposure Burden5.
Quantifying Healthcare Acquisition (which includes Transmission)
Recommended metricsfrom the
SHEA/HICPAC Position Paperwere the basis
for thenew MDRO and CDAD Module
Module Overview
National Healthcare Safety Network (NHSN)
Patient SafetyComponent
Device-Associated
Module
Medication-Associated
Module
MDROand
CDADModule
Procedure-Associated
Module
High-RiskInpatient InfluenzaVaccination Module
Goal of the MDRO and CDAD Module
Monitoring of MDRO and C. difficile infection (CDI) helps to evaluate local trends and changes in the occurrence of these pathogens and related infections.
This module provides a mechanism for facilities to report and analyze MDRO and CDI data, in order to inform infection control staff of the impact of targeted prevention efforts.
Organisms Monitored1) Methicillin-Resistant Staphylococcus aureus (MRSA)
(option w/ Methicillin-Sensitive S. aureus (MSSA)
2) Vancomycin-Resistant Enterococcus spp. (VRE)
3) Multidrug-Resistant (MDR) Klebsiella spp.
4) Multidrug-Resistant (MDR) Acinetobacter spp.
5) Clostridium difficile-Associated Disease (CDAD)
MDRO and C. difficile Current Definitions
MRSA: S. aureus testing oxacillin resistant;or positive from molecular testing for mecA and PBP2a
MSSA: S. aureus testing oxacillin intermediate or susceptible; or(option)
negative from molecular testing for mecA and PBP2a
VRE: Any Enterococcus spp. testing resistant to vancomycin
MDR-Klebsiella: Klebsiella spp. testing intermediate or resistant to ceftazidime or ceftriaxone
MDR-Acinetobacter: Acinetobacter spp. resistant to all agents tested within at least 3 antimicrobial classes, including -lactams, carbapenems aminoglycosides, and fluoroquinolones
C. difficile: Gastrointestinal System Infection-Gastroenteritis or Gastrointestinal System Infection-Gastrointestinal Tract where C. difficile is the associated pathogen
MRSA: S. aureus testing oxacillin resistant; or(positive from molecular testing for mecA and PBP2a)
MSSA: S. aureus testing oxacillin intermediate or susceptible; or(negative from molecular testing for mecA and PBP2a)
VRE: Any Enterococcus spp. testing resistant to vancomycin
MDR-Klebsiella: Klebsiella spp. testing intermediate or resistant to ceftazidime or cefotaxime/ceftriaxone or cefepime
MDR-Acinetobacter: Acinetobacter spp. testing intermediate or resistant to at least one agent within at least 3 antimicrobial classes of 6,
including: penicillins, carbapenems, aminoglycosides, cephalosporins, quinolones, or sulbactam
C. difficile: C. difficile is identified as the associated pathogen forGastrointestinal System Infection-Gastroenteritis or Gastrointestinal System Infection-Gastrointestinal Tract
MDRO and C. difficile Definitions for 2011
Reporting Requirements and OptionsActive participants must choose main reporting method
Infection Surveillance LabID Event Reporting
additional options then become available
Prevention Process Measures:• Adherence to Hand Hygiene• Adherence to Gown and Glove Use• Adherence to Active Surveillance Testing
Outcome Measures:• AST Prevalence / Incidence
Reporting MethodsLocation Specific:-
Select only a few locations or full facility coverage.
-
Report separately from each selected location in the facility.-
Separate denominators (patient days, admissions, encounters) for both locations.
Facility-Wide Inpatient or Facility Wide Outpatient:-
Options available only in the MDRO/CDAD Module and only for LabID Event reporting.
-
Report totals from throughout a facility’s inpatient or outpatient locations.-
Single denominators (either patient days and admissions for
FacWideIN , or encounters for FacWIDE OUT) for entire facility.
Monthly Reporting Plan for Lab ID Event
Enter both
for inpatient and outpatient facility wide
Infection Surveillance
Purpose: To collect MDRO or CDI data on NHSN-defined healthcare-associated infections (HAIs)
HAI: A localized or systemic condition resulting from an adverse reaction to the presence of an infectious agent or its toxin. There must be no evidence that the infection was present or incubating at the time of admission to the location.
Report for at least three months any time in a calendar year
Location specific reporting
Inpatient locations (where denominator data can be collected)
Infection Surveillance Analysis
MDRO/CDI Infection Incidence Density Rate
# of reported MDRO or CDI Infections = X 1000
# of Patient-Days
(stratified by time and location)
LabID Event ReportingPurpose: To calculate proxy measures of MDRO or CDI events,
exposures, healthcare acquisitions through monitoring and reporting data from positive clinical cultures.
LabID Event: A laboratory-identified event. First positive MDRO/CDI isolate collected for diagnosis/treatment for the patient in a location during a month. Only time a patient will have > 1 LabID Event reported for a location in a month is for bloods (MDRO) or stool (CDI), as these can be reported every 14 days.
Report for at least three consecutive
months in a calendar year
Location specific or Overall facility-wide reporting
Report all specimens or blood specimens only (for Facility-wide reporting)
Inpatient locations (no NICUs or Well Baby Nurseries for CDI) andOutpatient locations (no dialysis centers nor Well Baby Clinics)
Identifying an MDRO LabID Event (if Monitoring All
Specimens Only)
LabID Event (unique MDRO blood source)
NONot aLabIDEvent
YES MDROfrom blood≤
2 wks
YES
NONot aLabIDEvent
MDROSource= blood
NO
LabID Event (non-duplicate
isolate)
YES1st
incalendarmonth
MDRO isolate from any specimen
Begin Here
Categorization of LabID EventsNHSN Application Categorizes LabID Events as:
Community-Onset (CO): LabID Event collected as an outpatient or as an inpatient ≤
3 days after admission to the
facility (i.e., days 1 (admission), 2, or 3)
Healthcare Facility-Onset (HO): LabID Event specimen collected > 3 days after admission to the facility (i.e., on or after day 4)
Community-Onset Healthcare Facility Associated (CO- HCFA): LabID Event collected from a patient who was
discharged from the facility < 4 weeks prior to date stool specimen collected. * C diff only
LabID Event Reporting AnalysisSpecific Metrics Exposure Infection Acquisition
Admission Prevalence RateOverall Prevalence Rate
Bloodstream Infection Admission Prevalence RateBloodstream Infection Incidence or Incidence Density Rate
Overall MDRO Infection/Colonization Incidence or Incidence Density Rate
Location CDI Incidence RateFacility CDI Healthcare Facility-Onset Incidence RateFacility CDI Combined Incidence Rate
Infection Surveillance
LabID Events
LabID Events versus AST
LabID Event reporting
is ONLY for collecting and tracking positive cultures that are taken for “clinical”
purposes (i.e., for
diagnosis and treatment), which means NO active surveillance testing/cultures (AST/ASC) results are be included in this reporting of individual events.
Active Surveillance Testing (AST)
is for collecting and tracking positive cultures that are collected for surveillance purposes (e.g., nasal or rectal swabs) to identify patients that
are colonized with a specific organism (i.e., MRSA or VRE) at admission to a location and at discharge or transfer out of the location. The data are NOT collected on an individual basis, but instead are entered as aggregate counts.
Adherence to Prevention Process Measures
Required Minimum Reporting -
if chosen:
a) HH: at least 30 unannounced observations after HCW contact
with patient or objects near patientb) GG: at least 30 unannounced observations during HCW contact
with patient or objects near patient
c) AST: conducted on patient Admission or
Admission & Discharge for MRSA and/or VRE only on All or
those with No History
Report for at least one month in a calendar year
Location specific reporting (suggest same location as IS or LabID reporting)
Inpatient locations and Outpatient (for HH) locations
Process Measures Adherence Analysis
Adherence Rate to Process Measures
# Performed or Used = X 100
# Indicated or Eligible
AST Outcomes Measures
Purpose: To allow facilities to more accurately quantify exposure burden (prevalence) and/or healthcare acquisition (incidence) of MRSA and/or VRE
Report for at least one month in a calendar year
Location specific reporting:•
required same location where AST adherence is performed
•
suggest same location where Infection Surveillance or LabID Event reporting is conducted
Inpatient locations
AST Outcomes Measures Definitions
•
AST at Admission provides Prevalence data–
Known Positive •
Patient with documented MRSA or VRE colonization or infection in previous 12 months
–
Admission AST or Clinical Positive•
Patient with MRSA or VRE isolated from specimen collected on admission (≤
3 days)
•
AST at Discharge/Transfer provides Incidence data–
Patient with stay > 3 days–
No documented MRSA or VRE in previous 12 months or on admission (≤
3 days)–
MRSA or VRE isolated from specimen collected > 3 days after admission or at time of discharge/transfer
AST Outcome Measures Analysis
AST Incidence / Direct Acquisition
# of Discharge/Transfer AST and New Clinical Positives = X 1000
# of Patient-Days
AST Admission Prevalence
# of Admission AST/Clinical/Known Positives = X 100
# of Admissions
Analysis and Output
1) Generate a Dataset
Generation of a Data Set
is specific to User Login
2) Choose Output Options
3) Choose Reporting Option and Organism
4) Basic Run Options – Line Listing
5) Basic Run Options – Frequency Tables
6) Basic Run Options – Pie or Bar Charts
7) Basic Run Options – Rate Tables
Modify - Output Options
Modify – Line Listing
Modify – Rate Table
FYI: an “or”
command worksby using diagonal cells
Export ‘Analysis’ or ‘Output’ Data Set
“Export Analysis Data Set”: will export the data from the category through which you have navigated to get to the Modify screen.
“Export Output Data Set”: will export the data from the subset which you have specified on the Modify screen.
Export Data Set Facility Users Only
“Export Data”: will export all data in all categories ever entered for the facility.
NHSN Reference
Home Page:http://www.cdc.gov/nhsn
Questions